Trial Identifier: | D589BR00078 |
Sponsor: | AstraZeneca |
NCTID:: | NCT06172777 |
Start Date: | February 2024 |
Primary Completion Date: | August 2024 |
Study Completion Date: | August 2024 |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
No documents have been posted yet.
Country | Location |
---|---|
China | Beijing, China |
China | Changsha, China |
China | Chengdu, China |
China | Chongqing, China |
China | Dalian, China |
China | Erdos, China |
China | Fengcheng, China |
China | Fuyang, China |
China | Fuzhou, China |
China | Guangzhou, China |
China | Guiyang, China |
China | Haikou, China |
China | Hanchuan, China |
China | Hangzhou, China |
China | Haozhou, China |
China | Henan, China |
China | Jinan, China |
China | Jingzhou, China |
China | Kunming, China |
China | Mianyang, China |
China | Nanchang, China |
China | Nantong, China |
China | Ningbo, China |
China | Panzhou, China |
China | Qionghai, China |
China | Shanghai, China |
China | Shenyang, China |
China | Shenzhen, China |
China | Suining, China |
China | Suzhou, China |
China | Taiyuan, China |
China | Taizhou, China |
China | Tianjin, China |
China | Xinyang, China |
China | Yulin, China |
China | Yunnan, China |
China | Zhaotong, China |
China | Zhengzhou, China |
China | Zhuji, China |
China | Zigong, China |